[시장보고서]mRNA 치료제 수탁개발제조기관(CDMO) 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 적응증별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

mRNA 치료제 수탁개발제조기관(CDMO) 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 적응증별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Application, By Indication, By End-use, By Region, And Segment Forecasts, 2024 - 2030

상품코드 : 1511801

리서치사 : Grand View Research, Inc.

발행일 : 2024년 06월

페이지 정보 : 영문 144 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,272,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 9,662,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,443,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

mRNA 치료제 수탁개발제조기관(CDMO) 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, mRNA 치료제 수탁개발제조기관 세계 시장 규모는 2024년부터 2030년까지 11.28%의 CAGR을 기록하며 2030년까지 83억 5,000만 달러에 달할 것으로 예상됩니다.

mRNA 및 세포 전달 시스템의 기술 발전은 비용 효율성, 제조의 용이성, 이전에는 치료할 수 없었던 경로를 표적으로 삼을 수 있는 능력과 결합하여 의료에 혁명을 일으킬 수 있는 무한한 잠재력을 가지고 있습니다. mRNA 치료제를 개발하기 위한 R&D 투자 증가와 강력한 제품 파이프라인도 시장 성장에 힘을 실어주고 있습니다. 예를 들어, Moderna는 2023년 4분기 연구개발비가 2022년 동기 대비 16% 증가한 14억 달러에 달했다고 발표했습니다.

연구개발비는 회사의 거대세포바이러스(CMV) 백신, RSV 백신, COVID-19와 독감 혼합 백신, 개인맞춤형 신항원 요법을 통한 임상 제조 활동의 증가로 인한 것입니다. 이러한 요인들은 mRNA 치료제에 대한 연구 노력을 촉진할 것으로 예상됩니다. 또한, 미충족 의료 수요를 충족시키기 위한 새로운 치료제의 개발이 제품 시장에 변화를 가져오고 있습니다. 분자의 복잡성이 증가함에 따라 연구 및 제조 서비스에 대한 심층적인 지식과 새로운 분자 포맷의 지속가능한 발현 및 스케일업을 가능하게 하는 기술에 대한 필요성이 증가하고 있습니다. 바이오컨쥬게이션이나 이중특이성 항체 제작과 같은 플랫폼 기술은 개발 기간과 생산 기간을 크게 단축할 수 있어, 고객들은 시장 출시 기간을 단축하고 투자 리스크를 줄일 수 있는 숙련된 CDMO를 원하고 있습니다. 이에 따라 제약 및 생명공학 산업을 위한 제품을 설계 및 제조하는 CDMO에 대한 수요가 급증하고 있습니다.

mRNA 치료제 수탁개발제조기관 시장 보고서 하이라이트

바이러스 백신 분야는 2023년 100.00%의 점유율로 시장을 장악했습니다. 이 분야의 성장은 바이러스 감염(COVID-19) 치료를 위한 다양한 백신의 가용성 및 출시 증가에 기인합니다.
감염병 분야는 감염병 발병률 증가, 기존 백신에 비해 mRNA 백신의 여러 가지 장점, 새로운 임상 연구 및 파이프라인 분석, 제약 회사와 CDMO의 생산 협력 증가로 인해 2023년 가장 큰 시장 점유율을 차지했습니다.
바이오 기업의 최종 용도 부문이 2023년 60.00% 이상의 점유율을 차지하며 시장을 주도하고 있습니다. 이 부문의 성장을 주도하는 것은 mRNA 백신 제조를 위한 CDMO와의 제휴 및 협력과 같은 전략적 이니셔티브의 증가입니다.
아시아태평양은 2024년부터 2030년까지 10.83%의 가장 빠른 성장률을 기록할 것으로 예상됩니다. 인도, 중국 등 개발도상국의 제약회사 및 위탁생산 기관 수가 증가함에 따라 아시아태평양은 가까운 장래에 유럽과 북미를 추월할 가능성이 높습니다.

시장 진출 기업 분류
시장 상황 분석, 2022/2023년(히트맵 분석)
기업 개요
벤더 상황
주요 기업의 시장 점유율 분석, 2023년
Danaher(Aldevron)
Biomay AG
Bio-Synthesis, Inc.
eTheRNA
Kaneka Eurogentec S.A.
TriLink BioTechnologies
ApexBio Technology
BioNTech SE
BioCina
Lonza
Recipharm AB
Novo Holdings(Catalent, Inc.)
Samsung Biologics

ksm

영문 목차

영문목차

mRNA Therapeutics Contract Development & Manufacturing Organization Market Growth & Trends:

The global mRNA therapeutics contract development & manufacturing organization market size is expected to reach USD 8.35 billion by 2030, registering a CAGR of 11.28% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing technological advancements in mRNA and cellular delivery systems, coupled with their cost effectiveness, manufacturing simplicity, and ability to target previously undruggable pathways, have limitless potential to revolutionize medicine. This could represent lucrative growth opportunities for the market. Increasing R&D investments to develop mRNA therapeutics and a strong product pipeline are also propelling the market's growth. For instance, Moderna shared that R&D expenses for the fourth quarter of 2023 increased by 16% to USD 1.4 billion compared to the same quarter of 2022.

The R&D spending was driven by increased clinical manufacturing activities, with the company's Cytomegalovirus (CMV) vaccine, RSV vaccine, and combination vaccine against COVID-19 & flu, as well as its individualized neoantigen therapy. Such factors are expected to boost research efforts in mRNA therapeutics. In addition, developing novel therapeutics to address unmet medical needs is altering the product market. The rise in molecular complexity drives the need for in-depth knowledge in research and manufacturing services, as well as the technology to enable sustainable expression and scale-up of novel molecular formats. Platform technologies, such as those for bioconjugation or the creation of bispecific antibodies, can drastically shorten development and production times, and customers are looking for skilled CDMOs who can assist them shorten the time to market and reducing investment risk. Consequently, the need for CDMOs to design and produce goods for the pharmaceutical and biotechnology industries is growing exponentially.

mRNA Therapeutics Contract Development & Manufacturing Organization Market Report Highlights:

The viral vaccines segment dominated the market with a share of 100.00% in 2023. Growth in the segment can be attributed to the rising availability and launch of various vaccines for the treatment of viral infection (COVID-19)
The infectious diseases segment held the largest market share in 2023 due to the growing incidence of infectious diseases, several advantages of mRNA vaccine over conventional vaccines, emerging clinical studies & pipeline analysis, and increasing collaboration between pharmaceutical companies & CDMO for production
The biotech companies end-use segment dominated the market and accounted for a share of more than 60.00% in 2023. The segment growth is driven by increasing strategic initiatives, such as partnerships & collaborations with CDMOs, to manufacture mRNA vaccines
Asia Pacific is expected to register the fastest growth rate of 10.83% from 2024 to 2030. Due to the rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future

Chapter 1 Methodology and Scope

1.1 Market Segmentation and Scope
- 1.1.1 Regional Scope
1.2 Estimates And Forecast Timeline
1.3 Market Definition
1.4 Research Methodology
1.5 Information Procurement
- 1.5.1 Information Analysis
- 1.5.2 Market Formulation & Data Visualization
- 1.5.3 Data Validation & Publishing
1.6 Research Scope And Assumptions
- 1.6.1 Commodity Flow Analysis
- 1.6.2 Top Down Market Estimation
- 1.6.3 Region/Country Based Segment Share Calculation.
- 1.6.4 Multivariate Analysis
- 1.6.5 Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: CAGR Calculation
1.7 List of Secondary Sources
1.8 List of Abbreviations

Chapter 2 Executive Summary

2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Segment Snapshot
2.4 Competitive Landscape Snapshot

Chapter 3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Variables, Trends, & Scope

3.1 Market Lineage Outlook
- 3.1.1 Parent Market Outlook
- 3.1.2 Ancillary Market Outlook
  - 3.1.2.1 Global Recombinant Protein Therapeutics CDMO Market
3.2 Market Dynamics
- 3.2.1 Market Driver Analysis
  - 3.2.1.1 Rapid Adoption Of Mrna In Vaccine Development
  - 3.2.1.2 Multiple Research Efforts On Mrna Therapeutics
  - 3.2.1.3 Major Funding For Mrna Research
- 3.2.2 Market Restraint Analysis
  - 3.2.2.1 Availability of Low-cost Substitute Therapies
  - 3.2.2.2 High Research Cost
3.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Analysis Tools
- 3.3.1 Porter's Five Forces Analysis
- 3.3.2 Pestel Analysis
3.4 COVID-19 Impact Analysis

Chapter 4 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Application Analysis

4.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by Application Segment: Key Takeaways
4.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Application Movement Analysis
4.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by Application (USD Million)
4.4 Viral Vaccines
- 4.4.1 Viral Vaccines Market, 2018 - 2030 (USD Million)
4.5 Protein Replacement Therapies
- 4.5.1 Protein Replacement Therapies Market, 2018 - 2030 (USD Million)
4.6 Cancer Immunotherapies
- 4.6.1 Cancer Immunotherapies Market, 2018 - 2030 (USD Million)

Chapter 5 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Indication Analysis

5.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by Indication Segment: Key Takeaways
5.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Indication Movement Analysis
5.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by Indication (USD Million)
5.4 Infectious Diseases
- 5.4.1 Infectious Diseases Market, 2018 - 2030 (USD Million)
5.5 Metabolic & Genetic Diseases
- 5.5.1 Metabolic & Genetic Diseases Market, 2018 - 2030 (USD Million)
5.6 Cardiovascular & Cerebrovascular Diseases
- 5.6.1 Cardiovascular & Cerebrovascular Diseases Market, 2018 - 2030 (USD Million)

Chapter 6 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: End-use Analysis

6.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by End-use Segment: Key Takeaways
6.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: End-use Movement Analysis
6.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by End-use (USD Million)
6.4 Biotech Companies
- 6.4.1 Biotech Companies Market, 2018 - 2030 (USD Million)
6.5 Pharmaceutical Companies
- 6.5.1 Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
6.6 Government & Academic Research Institutes
- 6.6.1 Government & Academic Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 7 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Regional Analysis

7.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by Regional Segment: Key Takeaways
7.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO): Market Share Analysis, 2023 & 2030
7.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO): Market Estimates and Forecast, by Region (USD Million)
7.4 North America
- 7.4.1 North America Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.4.2 U.S.
  - 7.4.2.1 Key Country Dynamics
  - 7.4.2.2 Competitive Scenario
  - 7.4.2.3 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.4.3 Canada
  - 7.4.3.1 Key Country Dynamics
  - 7.4.3.2 Competitive Scenario
  - 7.4.3.3 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.5 Europe
- 7.5.1 Europe Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.5.2 UK
  - 7.5.2.1 Key Country Dynamics
  - 7.5.2.2 Competitive Scenario
  - 7.5.2.3 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.5.3 Germany
  - 7.5.3.1 Key Country Dynamics
  - 7.5.3.2 Competitive Scenario
  - 7.5.3.3 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.5.4 France
  - 7.5.4.1 Key Country Dynamics
  - 7.5.4.2 Competitive Scenario
  - 7.5.4.3 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.5.5 Italy
  - 7.5.5.1 Key Country Dynamics
  - 7.5.5.2 Competitive Scenario
  - 7.5.5.3 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.5.6 Spain
  - 7.5.6.1 Key Country Dynamics
  - 7.5.6.2 Competitive Scenario
  - 7.5.6.3 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.5.7 Denmark
  - 7.5.7.1 Key Country Dynamics
  - 7.5.7.2 Competitive Scenario
  - 7.5.7.3 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.5.8 Sweden
  - 7.5.8.1 Competitive Scenario
  - 7.5.8.2 Key Country Dynamics
  - 7.5.8.3 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.5.9 Norway
  - 7.5.9.1 Key Country Dynamics
  - 7.5.9.2 Competitive Scenario
  - 7.5.9.3 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.6 Asia Pacific
- 7.6.1 Asia Pacific Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (Usd Million
- 7.6.2 Japan
  - 7.6.2.1 Key Country Dynamics
  - 7.6.2.2 Competitive Scenario
  - 7.6.2.3 Japan Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.6.3 China
  - 7.6.3.1 Key Country Dynamics
  - 7.6.3.2 Competitive Scenario
  - 7.6.3.3 China Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.6.4 India
  - 7.6.4.1 Key Country Dynamics
  - 7.6.4.2 Competitive Scenario
  - 7.6.4.3 India Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.6.5 Australia
  - 7.6.5.1 Key Country Dynamics
  - 7.6.5.2 Competitive Scenario
  - 7.6.5.3 Australia Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.6.6 South Korea
  - 7.6.6.1 Key Country Dynamics
  - 7.6.6.2 Competitive Scenario
  - 7.6.6.3 South Korea Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.6.7 Indonesia
  - 7.6.7.1 Key Country Dynamics
  - 7.6.7.2 Competitive Scenario
  - 7.6.7.3 Indonesia Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.7 Latin America
- 7.7.1 Latin America Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.7.2 Brazil
  - 7.7.2.1 Key Country Dynamics
  - 7.7.2.2 Competitive Scenario
  - 7.7.2.3 Brazil Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.7.3 Mexico
  - 7.7.3.1 Key Country Dynamics
  - 7.7.3.2 Competitive Scenario
  - 7.7.3.3 Mexico Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.7.4 Argentina
  - 7.7.4.1 Key Country Dynamics
  - 7.7.4.2 Competitive Scenario
  - 7.7.4.3 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.8 MEA
- 7.8.1 Mea Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.8.2 South Africa
  - 7.8.2.1 Key Country Dynamics
  - 7.8.2.2 Competitive Scenario
- 7.8.3 Saudi Arabia
  - 7.8.3.1 Key Country Dynamics
  - 7.8.3.2 Competitive Scenario
  - 7.8.3.3 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.8.4 UAE
  - 7.8.4.1 Key Country Dynamics
  - 7.8.4.2 Competitive Scenario
  - 7.8.4.3 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
- 7.8.5 Kuwait
  - 7.8.5.1 Key Country Dynamics
  - 7.8.5.2 Competitive Scenario
  - 7.8.5.3 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)

Chapter 8 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Competitive Landscape

8.1. Market Participant Categorization
8.2. Market Position Analysis, 2022/2023 (Heat Map Analysis)
8.3. Company Profiles
- 8.3.1. Strategy Mapping
- 8.3.2. Service Launches
- 8.3.3. Acquisition
- 8.3.4. Partnerships/Agreements/Collaboration
- 8.3.5. Expansions
8.4. Vendor Landscape
- 8.4.1. Key company market share analysis, 2023
- 8.4.2. Danaher (Aldevron)
  - 8.4.2.1. Company overview
  - 8.4.2.2. Financial performance
  - 8.4.2.3. Product/service benchmarking
  - 8.4.2.4. Strategic initiatives
- 8.4.3. Biomay AG
  - 8.4.3.1. Company overview
  - 8.4.3.2. Financial performance
  - 8.4.3.3. Product/service benchmarking
  - 8.4.3.4. Strategic initiatives
- 8.4.4. Bio-Synthesis, Inc.
  - 8.4.4.1. Company overview
  - 8.4.4.2. Financial performance
  - 8.4.4.3. Product/service benchmarking
  - 8.4.4.4. Strategic initiatives
- 8.4.5. eTheRNA
  - 8.4.5.1. Company overview
  - 8.4.5.2. Financial performance
  - 8.4.5.3. Product/service benchmarking
  - 8.4.5.4. Strategic initiatives
- 8.4.6. Kaneka Eurogentec S.A.
  - 8.4.6.1. Company overview
  - 8.4.6.2. Financial performance
  - 8.4.6.3. Product/service benchmarking
  - 8.4.6.4. Strategic initiatives
- 8.4.7. TriLink BioTechnologies
  - 8.4.7.1. Company overview
  - 8.4.7.2. Financial performance
  - 8.4.7.3. Product/service benchmarking
  - 8.4.7.4. Strategic initiatives
- 8.4.8. ApexBio Technology
  - 8.4.8.1. Company overview
  - 8.4.8.2. Financial performance
  - 8.4.8.3. Product/service benchmarking
  - 8.4.8.4. Strategic initiatives
- 8.4.9. BioNTech SE
  - 8.4.9.1. Company overview
  - 8.4.9.2. Financial performance
  - 8.4.9.3. Product/service benchmarking
  - 8.4.9.4. Strategic initiatives
- 8.4.10. BioCina
  - 8.4.10.1. Company overview
  - 8.4.10.2. Financial performance
  - 8.4.10.3. Product/service benchmarking
  - 8.4.10.4. Strategic initiatives
- 8.4.11. Lonza
  - 8.4.11.1. Company overview
  - 8.4.11.2. Financial performance
  - 8.4.11.3. Product/service benchmarking
  - 8.4.11.4. Strategic initiatives
- 8.4.12. Recipharm AB
  - 8.4.12.1. Company overview
  - 8.4.12.2. Financial performance
  - 8.4.12.3. Product/service benchmarking
  - 8.4.12.4. Strategic initiatives
- 8.4.13. Novo Holdings (Catalent, Inc.)
  - 8.4.13.1. Company overview
  - 8.4.13.2. Financial performance
  - 8.4.13.3. Product/service benchmarking
  - 8.4.13.4. Strategic initiatives
- 8.4.14. Samsung Biologics
  - 8.4.14.1. Company overview
  - 8.4.14.2. Financial performance
  - 8.4.14.3. Product/service benchmarking
  - 8.4.14.4. Strategic initiatives

한글목차

mRNA 치료제 수탁개발제조기관(CDMO) 시장 성장과 동향

mRNA 치료제 수탁개발제조기관 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 mRNA 치료제 수탁개발제조기관(CDMO) 시장 : 변수, 동향, 범위

제4장 mRNA 치료제 수탁개발제조기관(CDMO) 시장 : 용도별 분석

제5장 mRNA 치료제 수탁개발제조기관(CDMO) 시장 : 적응증별 분석

제6장 mRNA 치료제 수탁개발제조기관(CDMO) 시장 : 최종 용도별 분석

제7장 mRNA 치료제 수탁개발제조기관(CDMO) 시장 : 지역별 분석

제8장 mRNA 치료제 수탁개발제조기관(CDMO) 시장 : 경쟁 상황